Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 9/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.41 |
| ▸ | CDC25B | P30305 | 9/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 4/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 6/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23150644 | 1.00 | CA2 (0.43) | CA2PTPN2PTPN1CDC25BPPARG | |
| SCHEMBL23150645 | 1.00 | CA2 (0.43) | CA2PTPN2PTPN1CDC25BPPARG | |
| SCHEMBL29836867 | 0.95 | NOS2 (0.45) | CA2PTPN2PTPN1CDC25BNOS2 | |
| SCHEMBL23150653 | 0.95 | CA2 (0.42) | CA2PTPN2PTPN1CDC25BPPARG | |
| SCHEMBL23150657 | 0.95 | CA2 (0.42) | CA2PTPN2PTPN1CDC25BPPARG | |
| SCHEMBL23150655 | 0.95 | CA2 (0.42) | CA2PTPN2PTPN1CDC25BPPARG | |
| SCHEMBL23150669 | 0.93 | NAMPT (0.41) | CA2PTPN2PTPN1CDC25BNOS2 | |
| SCHEMBL23150668 | 0.93 | NAMPT (0.41) | CA2PTPN2PTPN1CDC25BNOS2 | |
| SCHEMBL23150667 | 0.93 | NAMPT (0.41) | CA2PTPN2PTPN1CDC25BNOS2 | |
| SCHEMBL23150662 | 0.91 | CA2 (0.41) | CA2PTPN2PTPN1CDC25BPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530204-B2 | Biocatalytic synthesis of cryptophycin anticancer agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-12-20 | — | — | US | disclosed |
| EP-4038085-A1 | BIOCATALYTIC SYNTHESIS OF CRYPTOPHYCIN ANTICANCER AGENTS | The Regents of The University of Michigan (US) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021067460-A1 | BIOCATALYTIC SYNTHESIS OF CRYPTOPHYCIN ANTICANCER AGENTS | THE REGENTS OF THE UNIVERSITY OFMICHIGAN (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094942-A1 | BIOCATALYTIC SYNTHESIS OF CRYPTOPHYCIN ANTICANCER AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094942-A1 | BIOCATALYTIC SYNTHESIS OF CRYPTOPHYCIN ANTICANCER AGENTS | HCCS, ERG28, COASY | CA2 394/4885PTPN2 4281/4885PTPN1 4502/4885 |
| US-11530204-B2 | Biocatalytic synthesis of cryptophycin anticancer agents | HCCS, ERG28, COASY | CA2 394/4885PTPN2 4281/4885PTPN1 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.